source
- Argenx reports positive Phase 3 results for Vyvgart Hytrulo in myositisArgenx announced that its subcutaneous formulation of Vyvgart, named Vyvgart Hytrulo, met the primary endpoint in a late‑stage Phase 3 trial in patients with myositis. The trial combined participa…
- EyePoint shares tumble as Durayvu misses primary goal in wet AMD trialEyePoint, a Boston biotech, saw its market value drop by nearly $1 billion after its lead candidate Durayvu failed to demonstrate non-inferiority to aflibercept in a pivotal phase 3 trial for wet a…